Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide
Abstract
:Simple Summary
Abstract
1. Introduction
2. Methods
2.1. Study Design
2.2. Statistical Considerations
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Coley, W.B. Contribution to the knowledge of sarcoma. Ann. Surg. 1891, 14, 199–220. [Google Scholar] [CrossRef] [PubMed]
- Nauts, H.C.; E Swift, W.; Coley, B.L. The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, M.D., reviewed in the light of modern research. Cancer Res. 1946, 6, 205–216. [Google Scholar] [PubMed]
- De Angulo, G.; Hernandez, M.; Morales-Arias, J.; Herzog, C.E.; Anderson, P.; Wolff, J.; Kleinerman, E.S. Early Lymphocyte Recovery as a Prognostic Indicator for High-risk Ewing Sarcoma. J. Pediatr. Hematol. 2007, 29, 48–52. [Google Scholar] [CrossRef]
- DuBois, S.G.; Elterman, K.; Grier, H.E. Early Lymphocyte Recovery in Ewing Sarcoma. J. Pediatr. Hematol. 2007, 29, 351–352. [Google Scholar] [CrossRef]
- De Angulo, G.; Yuen, C.; Ms, S.L.P.; Anderson, P.M.; Zweidler-McKay, P.A. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML. Cancer 2007, 112, 407–415. [Google Scholar] [CrossRef]
- Porrata, L.; Ingle, J.; Litzow, M.R.; Geyer, S.; Markovic, S. Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplant. 2001, 28, 865–871. [Google Scholar] [CrossRef] [Green Version]
- Moore, C.; Eslin, D.; Levy, A.; Roberson, J.; Giusti, V.; Sutphin, R. Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma. Pediatr. Blood Cancer 2010, 55, 1096–1102. [Google Scholar] [CrossRef]
- Ray-Coquard, I.; Cropet, C.; Van Glabbeke, M.; Sebban, C.; Le Cesne, A.; Judson, I.; Tredan, O.; Verweij, J.; Biron, P.; Labidi, I.; et al. Lymphopenia as a Prognostic Factor for Overall Survival in Advanced Carcinomas, Sarcomas, and Lymphomas. Cancer Res. 2009, 69, 5383–5391. [Google Scholar] [CrossRef] [Green Version]
- Vasquez, L.; León, E.; Beltran, B.; Maza, I.; Oscanoa, M.; Geronimo, J. Pretreatment Neutrophil-to-Lymphocyte Ratio and Lymphocyte Recovery: Independent Prognostic Factors for Survival in Pediatric Sarcomas. J. Pediatr. Hematol. 2017, 39, 538–546. [Google Scholar] [CrossRef]
- Templeton, A.J.; Mcnamara, M.G.; Šeruga, B.; Vera-Badillo, F.E.; Aneja, P.; Ocaña, A.; Leibowitz-Amit, R.; Sonpavde, G.; Knox, J.J.; Tran, B.; et al. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Solid Tumors: A Systematic Review and Meta-Analysis. J. Natl. Cancer Inst. 2014, 106, dju124. [Google Scholar] [CrossRef] [Green Version]
- Idowu, O.K.; Ding, Q.; Taktak, A.F.G.; Chandrasekar, C.R.; Yin, Q. Clinical implication of pretreatment neutrophil to lymphocyte ratio in soft tissue sarcoma. Biomarkers 2012, 17, 539–544. [Google Scholar] [CrossRef] [PubMed]
- Skubitz, K.M.; Wilson, J.D.; Cheng, E.Y.; Lindgren, B.R.; Boylan, K.L.M.; Skubitz, A.P.N. Effect of chemotherapy on cancer stem cells and tumor-associated macrophages in a prospective study of preoperative chemotherapy in soft tissue sarcoma. J. Transl. Med. 2019, 17, 130. [Google Scholar] [CrossRef] [PubMed]
- Skubitz, K.M.; Hamdan, H.; Thompson, R.C. Ambulatory continuous infusion ifosfamide with oral etoposide in advanced sarcomas. Cancer 1993, 72, 2963–2969. [Google Scholar] [CrossRef]
- Nakamura, T.; Matsumine, A.; Matsubara, T.; Asanuma, K.; Uchida, A.; Sudo, A. The combined use of the neutrophil-lymphocyte ratio and C-reactive protein level as prognostic predictors in adult patients with soft tissue sarcoma. J. Surg. Oncol. 2013, 108, 481–485. [Google Scholar] [CrossRef]
- Szkandera, J.; Absenger, G.; Liegl-Atzwanger, B.; Pichler, M.; Stotz, M.; Samonigg, H.; Glehr, M.; Zacherl, M.; Stojakovic, T.; Gerger, A.; et al. Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients. Br. J. Cancer 2013, 108, 1677–1683. [Google Scholar] [CrossRef] [Green Version]
- Szkandera, J.; Gerger, A.; Liegl-Atzwanger, B.; Absenger, G.; Stotz, M.; Friesenbichler, J.; Trajanoski, S.; Stojakovic, T.; Eberhard, K.; Leithner, A.; et al. The lymphocyte/monocyte ratio predicts poor clinical outcome and improves the predictive accuracy in patients with soft tissue sarcomas. Int. J. Cancer 2013, 135, 362–370. [Google Scholar] [CrossRef]
- Jiang, L.; Jiang, S.; Situ, D.; Lin, Y.; Yang, H.; Li, Y.; Long, H.; Zhou, Z. Prognostic value of monocyte and neutrophils to lymphocytes ratio in patients with metastatic soft tissue sarcoma. Oncotarget 2015, 6, 9542–9550. [Google Scholar] [CrossRef] [Green Version]
- Maretty-Kongstad, K.; Aggerholm-Pedersen, N.; Keller, J.; Safwat, A. A Validated Prognostic Biomarker Score for Adult Patients with Nonmetastatic Soft Tissue Sarcomas of the Trunk and Extremities. Transl. Oncol. 2017, 10, 942–948. [Google Scholar] [CrossRef]
- Chan, J.Y.; Zhang, Z.; Chew, W.; Tan, G.F.; Lim, C.L.; Zhou, L.; Goh, W.L.; Poon, E.; Somasundaram, N.; Selvarajan, S.; et al. Biological significance and prognostic relevance of peripheral blood neutrophil-to-lymphocyte ratio in soft tissue sarcoma. Sci. Rep. 2018, 8, 1–9. [Google Scholar] [CrossRef] [Green Version]
- Que, Y.; Qiu, H.; Li, Y.; Chen, Y.; Xiao, W.; Zhou, Z.; Zhang, X. Preoperative platelet-lymphocyte ratio is superior to neutrophil-lymphocyte ratio as a prognostic factor for soft-tissue sarcoma. BMC Cancer 2015, 15, 648. [Google Scholar] [CrossRef] [Green Version]
- El-Hag, A.; A Clark, R. Down-regulation of human natural killer activity against tumors by the neutrophil myeloperoxidase system and hydrogen peroxide. J. Immunol. 1984, 133, 3291–3297. [Google Scholar]
- Petrie, H.T.; Klassen, L.W.; Kay, H.D. Inhibition of human cytotoxic T lymphocyte activity in vitro by autologous peripheral blood granulocytes. J. Immunol. 1985, 134, 230–234. [Google Scholar]
- El-Hag, A.; A Clark, R. Immunosuppression by activated human neutrophils. Dependence on the myeloperoxidase system. J. Immunol. 1987, 139, 2406–2413. [Google Scholar]
- Koga, Y.; Matsuzaki, A.; Suminoe, A.; Hattori, H.; Hara, T. Neutrophil-Derived TNF-Related Apoptosis-Inducing Ligand (TRAIL). Cancer Res. 2004, 64, 1037–1043. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhu, J.; De Tenbossche, C.G.P.; Canè, S.; Colau, D.; Van Baren, N.; Lurquin, C.; Schmitt-Verhulst, A.-M.; Liljeström, P.; Uyttenhove, C.; Van den Eynde, B.J. Resistance to cancer immunotherapy mediated by apoptosis of tumor-infiltrating lymphocytes. Nat. Commun. 2017, 8, 1404. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Veglia, F.; Sanseviero, E.; Gabrilovich, D.I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 2021, 21, 485–498. [Google Scholar] [CrossRef]
- Mastio, J.; Condamine, T.; Dominguez, G.; Kossenkov, A.V.; Donthireddy, L.; Veglia, F.; Lin, C.; Wang, F.; Fu, S.; Zhou, J.; et al. Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs. J. Exp. Med. 2019, 216, 2150–2169. [Google Scholar] [CrossRef] [Green Version]
- Braat, M.C.; Oosterhuis, B.; Koopmans, R.P.; Meewis, J.M.; Van Boxtel, C.J. Kinetic-dynamic modeling of lymphocytopenia induced by the combined action of dexamethasone and hydrocortisone in humans, after inhalation and intravenous administration of dexamethasone. J. Pharmacol. Exp. Ther. 1992, 262, 509–515. [Google Scholar]
- Ma, J.; Xie, Y.; Shi, Y.; Qin, W.; Zhao, B.; Jin, Y. Glucocorticoid-induced apoptosis requires FOXO3A activity. Biochem. Biophys. Res. Commun. 2008, 377, 894–898. [Google Scholar] [CrossRef]
- Anderson, P. Predicting and facilitating survival of pediatric cancer patients: The ALC story. Pediatr. Blood Cancer 2010, 55, 1041–1042. [Google Scholar] [CrossRef]
Variable: | N | Mean (SD) | Median [Min/Max] |
---|---|---|---|
Age in years | 69 | 52.5 (13.5) | 54.0 [20/79] |
Variable | N | Percent (%) | |
Gender | |||
Male | 42 | 62.9 | |
Female | 27 | 39.1 | |
AJCC stage | |||
3 | 44 | 63.8 | |
4 | 25 | 36.2 | |
Disease status at last f/up | |||
Alive, no progression | 34 | 49.3 | |
Alive, progression | 13 | 18.8 | |
Dead of disease | 22 | 31.9 |
ALC * | Hazard Ratio (HR) | 95% CI for HR | p-Value |
---|---|---|---|
Model 1: prior cycle 2 (n = 65) ALC ≥ 800 | 2.05 | 0.80, 5.28 | 0.136 |
Model 2: pre-surgery, all patients (n = 60) ALC ≥ 800 | 1.53 | 0.78, 3.01 | 0.220 |
Model 3: pre-surgery with all 4 cycles (n = 54) ALC ≥ 800 | 1.67 | 0.79, 3.54 | 0.181 |
Model 4: prior cycle 1 (n = 69) ALC (unit = 100 count increase) | 1.01 | 0.94, 1.08 | 0.761 |
Model 5: prior cycle 2 (n = 65) ALC (unit = 100 count increase) | 1.04 | 1.00, 1.07 | 0.053 |
Model 6: pre-surgery, all patients (n = 60) ALC (unit = 100 count increase) | 1.05 | 0.97, 1.14 | 0.221 |
Model 7: pre-surgery with all 4 cycles (n = 54) ALC (unit = 100 count increase) | 1.02 | 0.93, 1.12 | 0.679 |
ANC/ALC * | Hazard Ratio (HR) | 95% CI for HR | p-Value |
Model 1: prior cycle 1 (n = 69) ANC/ALC ≥ 2 | 2.66 | 0.82, 8.61 | 0.104 |
Model 2: prior cycle 1 (n = 69) ANC/ALC ≥ 5 | 1.43 | 0.70, 2.93 | 0.327 |
Model 3: prior cycle 2 (n = 65) ANC/ALC ≥ 5 | 0.70 | 0.37, 1.35 | 0.287 |
Model 4: pre-surgery, all patients (n = 60) ANC/ALC ≥ 5 | 1.65 | 0.85, 3.22 | 0.138 |
Model 5: pre-surgery with all 4 cycles (n = 54) ANC/ALC ≥ 5 | 1.32 | 0.63, 2.76 | 0.468 |
Model 6: prior cycle 1 (n = 69) ANC/ALC ratio | 1.03 | 0.93, 1.14 | 0.620 |
Model 7: prior cycle 2 (n = 65) ANC/ALC ratio | 0.92 | 0.82, 1.03 | 0.135 |
Model 8: pre-surgery, all patients (n = 60) ANC/ALC ratio | 1.04 | 0.96, 1.13 | 0.317 |
Model 9: pre-surgery with all 4 cycles (n = 54) ANC/ALC ratio | 1.00 | 0.91, 1.10 | >0.999 |
AMC | Hazard Ratio (HR) | 95% CI for HR | p-Value |
Model 1: prior cycle 1 (n = 69) AMC (unit = 100 count increase) | 1.05 | 0.95, 1.16 | 0.322 |
Model 2: prior cycle 2 (n = 64) AMC (unit = 100 count increase) | 1.15 | 1.03, 1.28 | 0.013 |
Model 3: pre-surgery, all patients (n = 61) AMC (unit = 100 count increase) | 1.01 | 0.90, 1.15 | 0.838 |
Model 4: pre-surgery with all 4 cycles (n = 54) AMC (unit = 100 count increase) | 0.95 | 0.81, 1.10 | 0.463 |
LMR = ALC/AMC * | Hazard Ratio (HR) | 95% CI for HR | p-Value |
Model 1: prior cycle 1 (n = 69) LMR ≥ 2.4 | 0.87 | 0.46, 1.64 | 0.661 |
Model 2: prior cycle 1 (n = 69) LMR continuous | 0.94 | 0.70, 1.27 | 0.693 |
Model 3: prior cycle 2 (n = 64) LMR continuous | 1.17 | 0.81, 1.69 | 0.393 |
Model 4: pre-surgery, all patients (n = 60) LMR continuous | 1.25 | 0.77, 2.03 | 0.372 |
Model 5: pre-surgery with all 4 cycles (n = 54) LMR continuous | 1.40 | 0.82, 2.40 | 0.220 |
PLR = platelets/ALC | Hazard Ratio (HR) | 95% CI for HR | p-Value |
Model 1: prior cycle 1 (n = 69) PLR ≥ 135 | 1.67 | 0.65, 4.24 | 0.286 |
Model 2: prior cycle 1 (n = 69) PLR ≥ 200 | 0.96 | 0.51, 1.81 | 0.907 |
Model 3: prior cycle 2 (n = 64) PLR ≥ 200 | 1.04 | 0.41, 2.69 | 0.931 |
Model 4: pre-surgery, all patients (n = 60) PLR ≥ 200 | 0.94 | 0.41, 2.16 | 0.885 |
Model 5: pre-surgery with all 4 cycles (n = 54) PLR ≥ 200 | 0.86 | 0.35, 2.13 | 0.745 |
Model 6: prior cycle 1 (n = 69) PLR continuous (unit = 100 count increase) | 0.94 | 0.69, 1.28 | 0.700 |
Model 7: prior cycle 2 (n = 64) PLR continuous (unit = 100 count increase) | 0.85 | 0.69, 1.05 | 0.131 |
Model 8: pre-surgery, all patients (n = 60) PLR continuous (unit = 100 count increase) | 0.96 | 0.80, 1.16 | 0.687 |
Model 9: pre-surgery with all 4 cycles (n = 54) PLR continuous (unit = 100 count increase) | 0.88 | 0.70, 1.10 | 0.259 |
ALC * | Hazard Ratio (HR) | 95% CI for HR | p-Value |
---|---|---|---|
Model 1: prior cycle 2 (n = 65) ALC ≥ 800 | 1.49 | 0.51, 4.31 | 0.468 |
Model 2: pre-surgery, all patients (n = 60) ALC ≥ 800 | 1.81 | 0.80, 4.10 | 0.156 |
Model 3: pre-surgery with all 4 cycles (n = 54) ALC ≥ 800 | 1.67 | 0.70, 3.98 | 0.251 |
Model 4: prior cycle 1 (n = 69) ALC (unit = 100 count increase) | 0.96 | 0.89, 1.04 | 0.342 |
Model 5: prior cycle 2 (n = 65) ALC (unit = 100 count increase) | 1.04 | 1.00, 1.08 | 0.050 |
Model 6: pre-surgery, all patients (n = 60) ALC (unit = 100 count increase) | 1.07 | 0.98, 1.17 | 0.129 |
Model 7: pre-surgery with all 4 cycles (n = 54) ALC (unit = 100 count increase) | 1.02 | 0.91, 1.14 | 0.757 |
ANC/ALC * | Hazard Ratio (HR) | 95% CI for HR | p-Value |
Model 1: prior cycle 1 (n = 69) ANC/ALC ≥ 2 | 6.27 | na | 0.039 † |
Model 2: prior cycle 1 (n = 69) ANC/ALC ≥ 5 | 2.08 | 0.95, 4.57 | 0.069 |
Model 3: prior cycle 2 (n = 65) ANC/ALC ≥ 5 | 1.15 | 0.53, 2.50 | 0.733 |
Model 4: pre-surgery, all patients (n = 60) ANC/ALC ≥ 5 | 1.77 | 0.81, 3,88 | 0.155 |
Model 5: pre-surgery with all 4 cycles (n = 54) ANC/ALC ≥ 5 | 1.59 | 0.69, 3.69 | 0.278 |
Model 6: prior cycle 1 (n = 69) ANC/ALC ratio | 1.09 | 0.99, 1.22 | 0.095 |
Model 7: prior cycle 2 (n = 65) ANC/ALC ratio | 0.95 | 0.84, 1.08 | 0.412 |
Model 8: pre-surgery, all patients (n = 60) ANC/ALC ratio | 1.02 | 0.94, 1.10 | 0.671 |
Model 9: pre-surgery with all 4 cycles (n = 54) ANC/ALC ratio | 1.05 | 0.95, 1.16 | 0.387 |
AMC | Hazard Ratio (HR) | 95% CI for HR | p-Value |
Model 1: prior cycle 1 (n = 69) AMC (unit = 100 count increase) | 1.09 | 0.98, 1.20 | 0.105 |
Model 2: prior cycle 2 (n = 64) AMC (unit = 100 count increase) | 1.21 | 1.07, 1.37 | 0.003 |
Model 3: pre-surgery, all patients (n = 61) AMC (unit = 100 count increase) | 1.11 | 0.98, 1.26 | 0.098 |
Model 4: pre-surgery with all 4 cycles (n = 54) AMC (unit = 100 count increase) | 1.03 | 0.88, 1.20 | 0.726 |
LMR = ALC/AMC * | Hazard Ratio (HR) | 95% CI for HR | p-Value |
Model 1: prior cycle 1 (n = 69) LMR ≥ 2.4 | 0.50 | 0.24, 1.03 | 0.062 |
Model 2: prior cycle 1 (n = 69) LMR continuous | 0.74 | 0.52, 1.06 | 0.105 |
Model 3: prior cycle 2 (n = 64) LMR continuous | 1.12 | 0.70, 1.79 | 0.641 |
Model 4: pre-surgery, all patients (n = 60) LMR continuous | 1.02 | 0.56, 1,83 | 0.960 |
Model 5: pre-surgery with all 4 cycles (n = 54) LMR continuous | 1.08 | 0.57, 2.03 | 0.823 |
PLR = platelets/ALC * | Hazard Ratio (HR) | 95% CI for HR | p-Value |
Model 1: prior cycle 1 (n = 69) PLR ≥ 135 | 1.36 | 0.48, 3.92 | 0.564 |
Model 2: prior cycle 1 (n = 69) PLR ≥ 200 | 1.07 | 0.51, 2.23 | 0.867 |
Model 3: prior cycle 2 (n = 64) PLR ≥ 200 | 0.91 | 0.31, 2.65 | 0.861 |
Model 4: pre-surgery, all patients (n = 60) PLR ≥ 200 | 0.91 | 0.34, 2.43 | 0.849 |
Model 5: pre-surgery with all 4 cycles (n = 54) PLR ≥ 200 | 0.73 | 0.27, 2.00 | 0.545 |
Model 6: prior cycle 1 (n = 69) PLR continuous (unit = 100 count increase) | 1.02 | 0.72, 1.46 | 0.898 |
Model 7: prior cycle 2 (n = 64) PLR continuous (unit = 100 count increase) | 0.84 | 0.65, 1.09 | 0.185 |
Model 8: pre-surgery, all patients (n = 60) PLR continuous (unit = 100 count increase) | 0.87 | 0.70, 1.08 | 0.211 |
Model 9: pre-surgery with all 4 cycles (n = 54) PLR continuous (unit = 100 count increase) | 0.89 | 0.69, 1.16 | 0.381 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Skubitz, K.M.; Domingo-Musibay, E.; Lindgren, B.R.; Cheng, E.Y. Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide. Cancers 2022, 14, 3419. https://doi.org/10.3390/cancers14143419
Skubitz KM, Domingo-Musibay E, Lindgren BR, Cheng EY. Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide. Cancers. 2022; 14(14):3419. https://doi.org/10.3390/cancers14143419
Chicago/Turabian StyleSkubitz, Keith M., Evidio Domingo-Musibay, Bruce R. Lindgren, and Edward Y. Cheng. 2022. "Prospective Trial of Neutrophil/Lymphocyte Ratio and Other Blood Counts as Biomarkers of Survival among Patients with High-Grade Soft Tissue Sarcomas Treated with Pegylated Liposomal Doxorubicin and Ifosfamide" Cancers 14, no. 14: 3419. https://doi.org/10.3390/cancers14143419